Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Ophthalmology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Retinitis Pigmentosa Clinical Trials

A listing of Retinitis Pigmentosa medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (5) clinical trials

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Males with a clinical diagnosis of X-linked retinitis pigmentosa (XLRP) caused by RPGR-ORF15 mutations will be asked to provide informed consent and will have a single blood or saliva sample obtained for DNA sequence analysis of genes known to cause XLRP, including the RPGR-ORF15 gene. All participants will be informed ...

Phase N/A

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa

A clinical trial of AAV-RPGR retinal gene therapy for patients with X-linked retinitis pigmentosa

Phase

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR)

This is an open-label phase I/II dose-escalation trial to determine the safety and efficacy of subretinal administration of AAV2 vector in participants with XLRP caused by mutations in RPGR.

Phase

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

This will be a non-randomized, open-label, Phase 1/2 dose escalation study. Approximately 30 participants will be enrolled. Each participant will receive the study agent by subretinal injection in one eye on a single occasion. Enrollment will begin with the lowest dose and will proceed to higher doses only after review ...

Phase

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

X-linked Retinitis Pigmentosa (XLRP) is a severe form of RP with early onset of nyctalopia and progression to legal blindness by the 3rd to 4th decade. Most affected males show symptomatic night blindness before the age of 10 years, are often myopic and show fundus abnormalities and ERG changes in ...

Phase N/A